Pharma BD Deal Intelligence

Roche Holding AG / mtm laboratories AG

2011 · Acquisition/Merger · $269M · Complete

Announcement Sentiment

100

Strongly positive

Roche/Ventana acquired German cervical-cancer diagnostics specialist mtm laboratories for €130M upfront (~$184M) plus up to €60M (~$85M) in milestones; total up to ~$269M. Complemented Roche's cobas HPV cervical screening platform.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Jul 19, 2011
Closed Aug 01, 2011
Deal value $269M
Deal type Acquisition/Merger
Therapeutic area Cervical cancer screening / pre-cancerous lesion detection
Indications Cervical cancer screening / pre-cancerous lesion detection
Key assets p16 INK4a-based cervical cancer diagnostic tests (CINtec)
Mechanism Immunohistochemistry/cytology biomarker (p16 tumor suppressor)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals